Fused pyrazine mono-N-oxides as bioreductive durgs. II cytotoxicity in human cells and oncogenicity in a rodent transformation assay

International Journal of Radiation Oncology Biology Physics

Volumn 34, Issue 1, 1996, Pages 79-84

  Langmuir, Virginia K ^a,d   Laderoute, Keith R ^a   Mendonca, Holly L ^a   Sutherland, Robert M ^a   Hei, Tom K ^b   Liu, Su Xian ^b   Hall, Eric J ^b   Naylor, Matthew A ^c   Adams, Gerald E ^c  

^a SRI INTERNATIONAL   (United States)

^b Columbia University ^*  (United States)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d ALZA CORPORATION   (United States)

Author keywords

Bioreductive drugs; Hypoxic cytotoxicity; Oncogenicity

Indexed keywords

1,2 DIHYDRO 4 PHENYLIMIDAZO[1,2 A]PYRIDO[3,2 E]PYRAZINE 5 OXIDE; 1,2 DIHYDRO 8 (4 METHYL 1 PIPERAZINYL) 4 PHENYLIMIDAZO[1,2 A]PYRIDO[3,2 E]PYRAZINE; 1,2 DIHYDRO 8 (4 METHYL 1 PIPERAZINYL) 4 PHENYLIMIDAZO[1,2 A]PYRIDO[3,2 E]PYRAZINE 5 OXIDE; 1,2 DIHYDRO 8 (4 METHYL 1 PIPERAZINYL) 4 PHENYLIMIDAZO[1,2 A]QUINOXALINE 5 OXIDE; PYRAZINE DERIVATIVE; RADIOSENSITIZING AGENT; RB 90740; RB 91701; RB 91725; RB 92816; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENICITY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HT29 CELLS; HUMANS; MICE; MICE, INBRED C3H; PYRAZINES; RADIOBIOLOGY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0030071333     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(95)02077-2     Document Type: Article

References (19)

1. Benedict, W. F.; Banerjee, A.; Gardner, A.; Jones, P. A. Induction of morphological transformation in mouse C3H 10T1/2 cells and chromosomal damage in hamster AT1 cells by cancer themotherapeutic agents. Cancer Res. 37:2202-2208; 1977.
2. Brown, J. M. Sensitizers and protectors in radiotherapy. Cancer 55:2222-2228; 1985.
3. Brown, J. M.; Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50:7745-7749; 1990.
4. Cole, S.; Stratford, I. J.; Bowler, J.; Nolan, J.; Wright, E. G.; Lorimore, S. A.; Adams, G. E. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice. Int. J. Radiat. Oncol. Biol. Phys. 21:387-395; 1991.
5. Coleman, N. C. Secondary neoplasms in patients treated for cancer: Etiology and perspective. Radiat. Res. 92:188-200; 1982.
6. Done, M. J.; Brown, J. M. Tumor-specific, schedule-dependent interaction between Tirapazamine (SR 4233) and cisplatin. Cancer Res. 53:4633-4636; 1993.
7. Fogh, J.; Trempe, G. New human tumor cell lines ch.5. 1975. In Fogh, J., ed. Human tumor cells in vitro. New York: Plenum Press; 1975:115-154.
8. Group, I. W. Cellular and molecular mechanisms of cell transformation and standardization of transformation assays of established cell lines for the prediction of carcinogenic chemicals: Overview and recommended protocols. Cancer Res. 45:2395-2399; 1985.
9. Hall, E. J. Finding a smoother pebble: A workshop summary. In: Chadwick, K. H.; Seymour, C.; Barnhart, B., eds. Cell transformation and radiation-induced cancer. Brussels: Adam Hilger; 1989:401-412.
10. Hall, E. J.; Hei, T. K. Oncogenic transformation of cells in culture: Pragmatic comparisons on oncogenicity, cellular and molecular mechanisms. Int. J. Radiat. Oncol. Biol. Phys. 12:1090-1921; 1986.
11. Hei, T. K.; Geard, C. R.; Osmak, R. S.; Hall, E. J. In vitro assessment of the oncogenic potential of nitroimidazole radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys. 11:1653-1658; 1985.
12. Hei, T. L.; Hall, E. J. Taxol, radiation and oncogenic transformation. Cancer Res. 53:1368-1371; 1993.
13. Hei, T. K.; He, Z. Y.; Piao, C. Q.; Hall, E. J. Studies with bifunctional bioreductive drugs: In vitro oncogenic transforming potential. Radiat. Res. 124:S44-S49; 1990.
14. Hei, T. K.; Komatsu, K.; Hall, E. J.; Zaider, M. Oncogenic transformation by charged particles of defined LET. Carcinogenesis 9:747-750; 1988.
15. Hei, T. K.; Piao, C. Q.; He, Z. Y.; Hall, E. J. Mechanism of oncogenicity for bioreductive drugs. Int. J. Radiat. Oncol. Biol. Phys. 22:747-750; 1992.
16. 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo. Radiat. Res. 132:351-358; 1992.
17. Naylor, M. A.; Stratford, I. J.; Stephens, M. A.; Nolan, J.; Sutton, B.; Fielden, E. M.; Adams, G. E. Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumor drugs: Part 1. 8-alkylamino-substituted phenylimidazo [1,2-a] quinoxalines. Anticancer Drug Design, 8:439-461; 1993.
18. Reznikoff, C. A.; Bertram, J.; Brankow, D. W.; Heidelberger, C. Quantitative and qualitative studies of chemical transformation of clonal mouse embryo cells sensitive to postconfluence inhibition of cell division. Cancer Res. 33:3239-3249; 1973.
19. Wilder, R. B.; Langmuir, V. K.; Mendonca, H. L.; Goris, M. L.; Knox, S. J. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. Cancer Res. 53:3022-3027; 1993.